WO2003090778A3 - Dna vaccine combined with an inducer of tumor cell apoptosis - Google Patents

Dna vaccine combined with an inducer of tumor cell apoptosis Download PDF

Info

Publication number
WO2003090778A3
WO2003090778A3 PCT/IB2003/001600 IB0301600W WO03090778A3 WO 2003090778 A3 WO2003090778 A3 WO 2003090778A3 IB 0301600 W IB0301600 W IB 0301600W WO 03090778 A3 WO03090778 A3 WO 03090778A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor cell
inducer
dna vaccine
cell apoptosis
vaccine combined
Prior art date
Application number
PCT/IB2003/001600
Other languages
French (fr)
Other versions
WO2003090778A2 (en
Inventor
Rose Ann Padua
Christine Chomienne
Dominique Charron
Original Assignee
Inst Nat Sante Rech Med
Univ Wales Medicine
Rose Ann Padua
Christine Chomienne
Dominique Charron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Wales Medicine, Rose Ann Padua, Christine Chomienne, Dominique Charron filed Critical Inst Nat Sante Rech Med
Priority to US10/512,475 priority Critical patent/US7381710B2/en
Priority to JP2003587410A priority patent/JP4354826B2/en
Priority to ES03717465T priority patent/ES2400178T3/en
Priority to AU2003222378A priority patent/AU2003222378A1/en
Priority to EP03717465A priority patent/EP1496937B1/en
Publication of WO2003090778A2 publication Critical patent/WO2003090778A2/en
Publication of WO2003090778A3 publication Critical patent/WO2003090778A3/en
Priority to US12/105,831 priority patent/US8673870B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the combination of a DNA vaccination strategy that makes use of a nucleic acid encoding an immunogenic polypeptide, with a non-immunosuppressive inducer of tumor cell differentiation and/or apoptosis or a tumor cell modifier, useful for cancer therapy. Vaccine compositions and kits are provided, as well as specific nucleic acid constructs that are particularly suitable for the preparation of such compositions.
PCT/IB2003/001600 2002-04-26 2003-04-24 Dna vaccine combined with an inducer of tumor cell apoptosis WO2003090778A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/512,475 US7381710B2 (en) 2002-04-26 2003-04-24 Combined DNA vaccine and biological modifiers for cancer therapy
JP2003587410A JP4354826B2 (en) 2002-04-26 2003-04-24 Combination of DNA vaccine and biological modifier for cancer treatment
ES03717465T ES2400178T3 (en) 2002-04-26 2003-04-24 DNA vaccine combined with an inducer of tumor cell apoptosis
AU2003222378A AU2003222378A1 (en) 2002-04-26 2003-04-24 Dna vaccine combined with an inducer of tumor cell apoptosis
EP03717465A EP1496937B1 (en) 2002-04-26 2003-04-24 Dna vaccine combined with an inducer of tumor cell apoptosis
US12/105,831 US8673870B2 (en) 2002-04-26 2008-04-18 Combined DNA vaccine and biological modifiers for cancer therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02291069.9 2002-04-26
EP02291069A EP1356820A1 (en) 2002-04-26 2002-04-26 DNA vaccine combined with an inducer of tumor cell apoptosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/105,831 Continuation US8673870B2 (en) 2002-04-26 2008-04-18 Combined DNA vaccine and biological modifiers for cancer therapy

Publications (2)

Publication Number Publication Date
WO2003090778A2 WO2003090778A2 (en) 2003-11-06
WO2003090778A3 true WO2003090778A3 (en) 2004-01-22

Family

ID=28686019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/001600 WO2003090778A2 (en) 2002-04-26 2003-04-24 Dna vaccine combined with an inducer of tumor cell apoptosis

Country Status (6)

Country Link
US (2) US7381710B2 (en)
EP (5) EP1356820A1 (en)
JP (1) JP4354826B2 (en)
AU (1) AU2003222378A1 (en)
ES (1) ES2400178T3 (en)
WO (1) WO2003090778A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356820A1 (en) * 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) DNA vaccine combined with an inducer of tumor cell apoptosis
CN102439150A (en) * 2009-03-27 2012-05-02 法国国家健康医学研究院 Kanamycin antisense nucleic acid for the treatment of cancer
US20140127215A1 (en) * 2010-12-29 2014-05-08 Cangene Corporation Clostridium difficile antigens
US20170216430A1 (en) * 2014-08-04 2017-08-03 Nitto Denko Corporation Immune-induction-promoting composition including nuclear receptor ligand, and vaccine pharmaceutical composition
US20180296663A1 (en) * 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
CN107474115B (en) * 2016-06-08 2020-09-15 胡卓伟 Polypeptide and application thereof in preparing medicine for treating and/or preventing tumors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5571694A (en) * 1989-11-28 1996-11-05 Evans Medical Limited Expression of tetanus toxin fragment C in yeast
US5716982A (en) * 1995-06-07 1998-02-10 Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences Retinoids and methods of use of same
WO1999024029A1 (en) * 1997-11-10 1999-05-20 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
WO2001078700A2 (en) * 2000-04-13 2001-10-25 Frederic Geissmann Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DE3669503D1 (en) 1985-01-07 1990-04-19 Syntex Inc SURFACE-ACTIVE N- (OMEGA, OMEGA-1-DIALKOXY) - AND N- (OMEGA, OMEGA-1-DIALKENOXY) -ALK-1-YL-N, N, N-TRISUBSTITUTED AMMONIUM COMPOUNDS, THEIR PRODUCTION AND THEIR CONTAINERS.
US5015580A (en) 1987-07-29 1991-05-14 Agracetus Particle-mediated transformation of soybean plants and lines
DE69032284T2 (en) 1989-03-21 1998-10-08 Vical, Inc., San Diego, Calif. EXPRESSION OF EXOGENOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBLE
DK0431135T3 (en) 1989-06-26 2003-07-21 Powderject Vaccines Inc Particle-mediated transformation of somatic animal cells
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DK0584348T3 (en) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetic vaccine against immunodeficiency viruses
CA2131620A1 (en) 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
ATE260679T1 (en) 1992-04-03 2004-03-15 Univ California SELF-ORGANIZING POLYNUCLEOTIDE DELIVERY SYSTEM CONTAINING AN AMPHIPHATIC PEPTIDE
AU675702B2 (en) 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
ES2211882T3 (en) 1993-07-14 2004-07-16 The Regents Of The University Of California AUTOMOTIVE POLINUCLEOTIDE ASSIGNMENT SYSTEM THAT INCLUDES DENDRIMEROS POLICATIONS.
CA2168459C (en) * 1993-07-30 2002-10-01 Mohammed Anjam Khan Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
WO1996018733A2 (en) * 1994-12-14 1996-06-20 Innovir Laboratories, Inc. Ribozyme-mediated inactivation of leukemia-associated rna
EP1356820A1 (en) * 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) DNA vaccine combined with an inducer of tumor cell apoptosis
CN102439150A (en) * 2009-03-27 2012-05-02 法国国家健康医学研究院 Kanamycin antisense nucleic acid for the treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571694A (en) * 1989-11-28 1996-11-05 Evans Medical Limited Expression of tetanus toxin fragment C in yeast
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
US5716982A (en) * 1995-06-07 1998-02-10 Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences Retinoids and methods of use of same
WO1999024029A1 (en) * 1997-11-10 1999-05-20 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
WO2001078700A2 (en) * 2000-04-13 2001-10-25 Frederic Geissmann Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CATHERINE A KING ET AL: "DNA vaccines with single-chain Fv fused to fragment C of tetanus toxi induce protective immunity against lymphoma and myeloma", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 11, November 1998 (1998-11-01), pages 1281 - 1286, XP002173090, ISSN: 1078-8956 *
DEAGLIO SILVIA ET AL: "Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells", LEUKEMIA RESEARCH, vol. 25, no. 3, March 2001 (2001-03-01), pages 227 - 235, XP002260675, ISSN: 0145-2126 *
SHAO W ET AL: "ARSENIC TRIOXIDE AS AN INDUCER OF APOPTOSIS AND LOSS OF PML/RARA PROTEIN IN ACUTE PROMYELOCYTIC LEUKEMIA CELLS", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 90, no. 2, 21 January 1998 (1998-01-21), pages 124 - 133, XP000901182, ISSN: 0027-8874 *
STEPHENSEN C B ET AL: "RETINOIC ACID MODULATES EX VIVO TH1/TH2 PHENOTYPE DEVELOPMENT OF NAIVE T-CELLS FROM DO11.10 T-CELL RECEPTOR TRANSGENIC MICE", FASEB JOURNAL (FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY), BETHESDA, US, vol. 15, no. 5, 8 March 2001 (2001-03-08), pages A1093,AN83701, XP008009249, ISSN: 0892-6638 *
STEVENSON F K: "DNA VACCINES AGAINST CANCER: FROM GENES TO THERAPY", ANNALS OF ONCOLOGY, KLUWER, DORDRECHT, NL, vol. 10, no. 12, December 1999 (1999-12-01), pages 1413 - 1418, XP001068765, ISSN: 0923-7534 *

Also Published As

Publication number Publication date
EP2272528A3 (en) 2011-07-06
JP4354826B2 (en) 2009-10-28
EP2272527A3 (en) 2011-07-06
EP2272529A2 (en) 2011-01-12
JP2005538698A (en) 2005-12-22
AU2003222378A1 (en) 2003-11-10
EP2272528A2 (en) 2011-01-12
EP2272529A3 (en) 2011-06-22
US7381710B2 (en) 2008-06-03
WO2003090778A2 (en) 2003-11-06
US8673870B2 (en) 2014-03-18
EP1496937B1 (en) 2013-01-16
EP2272527A2 (en) 2011-01-12
US20080213314A1 (en) 2008-09-04
AU2003222378A8 (en) 2003-11-10
ES2400178T3 (en) 2013-04-08
EP1496937A2 (en) 2005-01-19
US20060079470A1 (en) 2006-04-13
EP1356820A1 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
WO2005047458A3 (en) Modified recombinant vaccina viruses and other microorganisms, uses thereof
WO2005003296A3 (en) Albumin fusion proteins
NO20055209L (en) Peptabody for cancer treatment
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (en) Albumin fusion proteins.
WO2003000928A3 (en) Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
WO2006103562A3 (en) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
EP1712243A4 (en) Gene therapy for tumor using minus-strand rna viral vectors encoding immunostimulatory cytokines
WO2003030821A3 (en) Albumin fusion proteins
WO2004035732A3 (en) Human polypeptides encoded by polynucleotides and methods of their use
WO2008137881A3 (en) Ehrlichia ewingii proteins, nucleic acids, and methods of their use
PL1675954T3 (en) Nucleic acids useful for triggering tumor cell lethality
WO2000053776A3 (en) Human kallikrein-like genes
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2003090778A3 (en) Dna vaccine combined with an inducer of tumor cell apoptosis
WO2004076614A3 (en) Human nucleic acid sequences obtained from prostatic carcinomas
EP1613345A4 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2004031354A3 (en) Human sarcoma-associated antigens
WO2004020591A3 (en) Methods of use for novel human polypeptides encoded by polynucleotides
WO2005049793A3 (en) Methods and compositions for combinatorial approaches to cancer gene therapy
ATE315406T1 (en) SEMI-ALLOGENE ANTITUMOR VACCINE WITH HLA-HAPLO-IDENTIAL ANTIGEN-PRESENTING CELLS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003717465

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003587410

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003717465

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006079470

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10512475

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10512475

Country of ref document: US